Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

249 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The promise of DNA damage response inhibitors for the treatment of glioblastoma.
Majd NK, Yap TA, Koul D, Balasubramaniyan V, Li X, Khan S, Gandy KS, Yung WKA, de Groot JF. Majd NK, et al. Among authors: yap ta. Neurooncol Adv. 2021 Feb 4;3(1):vdab015. doi: 10.1093/noajnl/vdab015. eCollection 2021 Jan-Dec. Neurooncol Adv. 2021. PMID: 33738447 Free PMC article. Review.
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer.
Jhaveri K, Burris Rd HA, Yap TA, Hamilton E, Rugo HS, Goldman JW, Dann S, Liu F, Wong GY, Krupka H, Shapiro GI. Jhaveri K, et al. Among authors: yap ta. Expert Rev Anticancer Ther. 2021 Oct;21(10):1105-1124. doi: 10.1080/14737140.2021.1944109. Epub 2021 Sep 1. Expert Rev Anticancer Ther. 2021. PMID: 34176404 Free article. Review.
PRMT1-dependent regulation of RNA metabolism and DNA damage response sustains pancreatic ductal adenocarcinoma.
Giuliani V, Miller MA, Liu CY, Hartono SR, Class CA, Bristow CA, Suzuki E, Sanz LA, Gao G, Gay JP, Feng N, Rose JL, Tomihara H, Daniele JR, Peoples MD, Bardenhagen JP, Geck Do MK, Chang QE, Vangamudi B, Vellano C, Ying H, Deem AK, Do KA, Genovese G, Marszalek JR, Kovacs JJ, Kim M, Fleming JB, Guccione E, Viale A, Maitra A, Emilia Di Francesco M, Yap TA, Jones P, Draetta G, Carugo A, Chedin F, Heffernan TP. Giuliani V, et al. Among authors: yap ta. Nat Commun. 2021 Jul 30;12(1):4626. doi: 10.1038/s41467-021-24798-y. Nat Commun. 2021. PMID: 34330913 Free PMC article.
Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.
Yap TA, Fontana E, Lee EK, Spigel DR, Højgaard M, Lheureux S, Mettu NB, Carneiro BA, Carter L, Plummer R, Cote GM, Meric-Bernstam F, O'Connell J, Schonhoft JD, Wainszelbaum M, Fretland AJ, Manley P, Xu Y, Ulanet D, Rimkunas V, Zinda M, Koehler M, Silverman IM, Reis-Filho JS, Rosen E. Yap TA, et al. Nat Med. 2023 Jun;29(6):1400-1411. doi: 10.1038/s41591-023-02399-0. Epub 2023 Jun 5. Nat Med. 2023. PMID: 37277454 Free PMC article. Clinical Trial.
PARP inhibitors: enhancing efficacy through rational combinations.
Bhamidipati D, Haro-Silerio JI, Yap TA, Ngoi N. Bhamidipati D, et al. Among authors: yap ta. Br J Cancer. 2023 Oct;129(6):904-916. doi: 10.1038/s41416-023-02326-7. Epub 2023 Jul 10. Br J Cancer. 2023. PMID: 37430137 Free PMC article. Review.
UBA1 inhibition sensitizes cancer cells to PARP inhibitors.
Awasthi S, Dobrolecki LE, Sallas C, Zhang X, Li Y, Khazaei S, Ghosh S, Jeter CR, Liu J, Mills GB, Westin SN, Lewis MT, Peng W, Sood AK, Yap TA, Yi SS, McGrail DJ, Sahni N. Awasthi S, et al. Among authors: yap ta. Cell Rep Med. 2024 Dec 17;5(12):101834. doi: 10.1016/j.xcrm.2024.101834. Epub 2024 Dec 2. Cell Rep Med. 2024. PMID: 39626673 Free PMC article.
249 results